Target intelligence / Profile preview

Transmembrane protein 63A (TMEM63A)

Target
TMEM63A
Molecular classification
Ion channel, Mechanosensitive channel, Transmembrane protein, Cation channel
01

Overview

Transmembrane protein 63A is a mechanosensitive cation channel predominantly found in animal cells, evolutionarily related to the OSCA family in plants. TMEM63A forms a monomeric, high-threshold mechanosensitive ion channel located at the plasma membrane and, in some contexts, the lysosome. It is activated by mechanical stimuli such as membrane stretch or osmotic shifts and mediates the influx of cations, including Ca2+ and Na+. TMEM63A is critical for oligodendrocyte-dependent myelination in the central nervous system and crucial in alveolar type I and II epithelial cells for surfuctant release and respiratory function. Mutations in TMEM63A are causative for infantile hypomyelinating leukodystrophy 19 (HLD19), and variants have been associated with other neurodevelopmental disorders due to altered channel or scramblase function. TMEM63A is being investigated as a potential therapeutic target due to its essential physiological roles in mechanotransduction, although no modulatory drugs are clinically available at this time.

Other names
Mechanosensitive cation channel TMEM63AKIAA0489KIAA0792hTMEM63AHLD19CSC1-like protein 1
02

Mechanism of action

As no drugs are listed, mechanisms of drug action are not established; mechanistically, channel activation produces cation influx in response to mechanical force

03

Biological functions

Mechanosensation (mechanical force detection/transduction)Ion transport (cation influx, including Ca2+)Regulation of myelination (central nervous system)Regulation of surfactant release (lung function)Lysosomal mechanosensitivityCell migration, proliferation, differentiation (inferred from mechanosensation)
04

Disease associations

Neurodevelopmental disorder (e.g., hypomyelinating leukodystrophy 19/HLD19)Respiratory failure (lung surfactant regulation)Potential involvement in inflammatory processesOther neurological disorders (potentially due to channelopathies)
05

Safety considerations

Loss-of-function variants lead to defective myelination and neurological deficitsChannel dysfunction may trigger neurodevelopmental or respiratory disordersTargeting mechanosensitive channels could theoretically disturb CNS myelination or lung function
06

Interacting drugs

None specifically known or clinically approved as of current literature; no pharmacological modulators are established
07

Biomarkers

Mutations in TMEM63A linked to hypomyelinating leukodystrophy 19 (HLD19)Functional presence or activity variations in oligodendrocytes or alveolar epithelial cells

Beyond the preview

Go deeper on Transmembrane protein 63A (TMEM63A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transmembrane protein 63A (TMEM63A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call